BiPar Sciences
Innovative therapies harnessing the power of PARP inhibitors to combat advanced cancers
est. 2002
Xilio Therapeutics, Inc.
Focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients
96 employees · est. 2016 · Waltham, United States
BiPar Sciences is the older company (2002 vs 2016).
1 signal in the last 90 days
Side-by-Side Comparison
| Metric | BiPar Sciences | Xilio Therapeutics, Inc. |
|---|---|---|
| Founded | ||
| Founded | 2002 older | 2016 |
| Headquarters | ||
| Headquarters | Not tracked yet | Waltham, United States |
| Employees | ||
| Employees | Not tracked yet | 96 |
| Industry | ||
| Industry | Biotechnology, Health Care, Pharmaceutical | Biopharma, Biotechnology, Health Care |
| Funding Stage | ||
| Funding Stage | Series C | Post Ipo Equity |
| Total Funding | ||
| Total Funding | $74.97M | $244.30M |
| Funding Rounds | ||
| Funding Rounds | 8 | 5 |
| Services | ||
| Services | Not tracked yet | Development of tumor-activated biologics, Clinical and preclinical immunotherapy research, Platform for tumor-selective activation therapies |
| Target Customers | ||
| Target Customers | Not tracked yet | Cancer Patients, Healthcare Providers, Clinical Researchers, Pharmaceutical Companies, Oncologists |
| Taxonomy | ||
| Taxonomy | BiPar Sciences, PARP Inhibitors, Cancer Therapies, BSI-201, Oncology, Venture Capital, Acquisition, Sanofi-Aventis, Clinical Trials, Breast Cancer, Ovarian Cancer, Tumor Treatment, Drug Development, Pharmaceutical Industry | Immunotherapy, Cancer Research, Clinical-stage Biopharmaceutical, Tumor-selective Therapies, Waltham, Massachusetts, Engineered Antibodies, Cytokines, Chemokines, Immuno-oncology Therapies, Cancer Treatment, Therapeutic Technology, Clinical Responses, Patient Outcomes, Immune System Activation |
| Website | ||
| Website | biparsciences.com | xiliotx.com |
About BiPar Sciences
BiPar Sciences, based in Brisbane, CA, is a biotechnology company focused on developing innovative therapies utilizing PARP inhibitors to combat advanced cancers. The company's leading experimental drug, BSI-201, is currently undergoing mid-phase trials aimed at treating advanced breast cancer, ovar...
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., established in 2016, is a promising player in the biopharmaceutical arena, headquartered in the United States. This Waltham, Massachusetts-based company is making significant strides in the fight against cancer by developing innovative therapeutic solutions. At the heart o...
We will tell you when either one moves
BounceWatch watches BiPar Sciences and Xilio Therapeutics, Inc. for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at BiPar Sciences and Xilio Therapeutics, In... — by email.
Frequently Asked Questions
Compare BiPar Sciences with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at BiPar Sciences on 11 Sep 2024, and Xilio Therapeutics, Inc. on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.